Efficacy of tacrolimus treatment in two-dose single-group controlled trial for patients with refractory infertility
Journal of Reproductive Immunology · 2026-06 · 175 · 104904
DOI: 10.1016/j.jri.2026.104904 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Reproductive Immunology, 2026-06. Verfasst von Michi Hisano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Women's Health Center, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Infertility, Female, Tacrolimus, Th1 Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, National Center for Child Health and Development.
Abstract (Originalsprache)
In this clinical trial, we aimed to confirm that immunosuppressant tacrolimus could be an effective and safe treatment option for patients with unexplained refractory infertility. Trial participants were women aged between 18 and 40 with refractory infertility who did not have underlying factors despite appropriate infertility evaluation and did have a Th1-dominant cytokine pattern defined as a Th1/Th2 cell ratio ≥ 10.3 in peripheral blood. Patients were randomly assigned (2:1 ratio) to receive immunosuppressive therapy with tacrolimus at a daily dose of 2 (low dose) or 4 (high dose) mg. Tacrolimus was orally administered for 16 days, starting 2 days before embryo transfer. The primary efficacy outcome was the presence of clinical pregnancy 3 weeks after embryo transfer. The clinical pregnancy proportion in the low- and high-dose groups was tested against the assumed proportion of 5% in the untreated group using a one-sided exact binomial test with a significance level of 0.0125. In the full analysis set, the proportion of clinical pregnancy at 3 weeks after embryo transfer was 66.7% (95% CI, 38.4-88.2) and 55.6% (95% CI, 21.2-86.3) in the low- and high-dose groups, respectively (p < 0.0001 for both). Immunosuppressive therapy with tacrolimus is a viable treatment option for patients with infertility who exhibit a Th1-dominant cytokine pattern without underlying factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Women's Health Center, National Center for Child Health and Development, Tokyo, Japan.
- Center for Reproductive Medicine and Implantation Research, Sugiyama Clinic Shinjuku, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.
- Department of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
- Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan.
- Showa Medical University Research Administration Center, Showa Medical University, Tokyo, Japan.
Förderung
- Japan Agency for Medical Research and Development
- National Center for Child Health and Development
Zitieren
APA
Hisano, M., Nakagawa, K., Ono, M., Yoshino, O., Saito, T., Hirota, Y., Inoue, E., Imai, S., Kikuchi, K., Nakamura, H., & Yamaguchi, K. (2026). Efficacy of tacrolimus treatment in two-dose single-group controlled trial for patients with refractory infertility. Journal of Reproductive Immunology, 175, 104904. https://doi.org/10.1016/j.jri.2026.104904
Vancouver
Hisano M, Nakagawa K, Ono M, Yoshino O, Saito T, Hirota Y, et al. Efficacy of tacrolimus treatment in two-dose single-group controlled trial for patients with refractory infertility. Journal of Reproductive Immunology. 2026;175:104904. doi:10.1016/j.jri.2026.104904
BibTeX
@article{Hisano2026,
author = {Hisano, Michi and Nakagawa, Koji and Ono, Masanori and Yoshino, Osamu and Saito, Takakazu and Hirota, Yasushi and Inoue, Eisuke and Imai, Shoko and Kikuchi, Kayoko and Nakamura, Hidefumi and Yamaguchi, Koushi},
title = {Efficacy of tacrolimus treatment in two-dose single-group controlled trial for patients with refractory infertility},
journal = {Journal of Reproductive Immunology},
year = {2026},
volume = {175},
pages = {104904},
doi = {10.1016/j.jri.2026.104904}
}
EUVIMED